{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=24", "query": { "intervention": "Open Label Extension", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 2288, "total_pages": 229, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T12:52:03.690Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06358651", "title": "Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Social Anxiety Disorder" ], "interventions": [ { "name": "Fasedienol Nasal Spray", "type": "DRUG" }, { "name": "Placebo Nasal Spray", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VistaGen Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 238, "start_date": "2024-03-28", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lafayette", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06358651" }, { "nct_id": "NCT05337553", "title": "A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spinal Muscular Atrophy", "Neuromuscular Diseases", "SMA" ], "interventions": [ { "name": "taldefgrobep alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 269, "start_date": "2022-07-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 30, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05337553" }, { "nct_id": "NCT02724228", "title": "A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "BMN 111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioMarin Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 30, "start_date": "2016-01-26", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 6, "location_summary": "Oakland, California • Torrance, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02724228" }, { "nct_id": "NCT02632721", "title": "A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "BI 836858", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2016-06-16", "completion_date": "2023-01-16", "has_results": true, "last_update_posted_date": "2024-03-19", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Chicago, Illinois • Lake Success, New York + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Success", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632721" }, { "nct_id": "NCT04468984", "title": "Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis (MF)" ], "interventions": [ { "name": "Navitoclax", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Best Available Therapy (BAT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2020-08-31", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 41, "location_summary": "Chandler, Arizona • Springdale, Arkansas • Duarte, California + 34 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04468984" }, { "nct_id": "NCT00866775", "title": "Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy With Simple or Complex Partial Onset Seizures" ], "interventions": [ { "name": "Eslicarbazepine acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 193, "start_date": "2009-04", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 103, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866775" }, { "nct_id": "NCT00694109", "title": "An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lipid Metabolism, Inborn Errors", "Hypercholesterolemia, Autosomal Dominant", "Hyperlipidemias", "Metabolic Diseases", "Hyperlipoproteinemia Type II", "Metabolism, Inborn Errors", "Genetic Diseases, Inborn", "Infant, Newborn, Diseases", "Metabolic Disorder", "Congenital Abnormalities", "Hypercholesterolemia", "Hyperlipoproteinemias", "Dyslipidemias", "Lipid Metabolism Disorders" ], "interventions": [ { "name": "Mipomersen Sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kastle Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 144, "start_date": "2008-04", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-09-09", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 20, "location_summary": "Mission Viejo, California • Newport Beach, California • Bridgeport, Connecticut + 17 more", "locations": [ { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694109" }, { "nct_id": "NCT00475800", "title": "Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis" ], "interventions": [ { "name": "Lumiracoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 833, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-05-21", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 5, "location_summary": "Tucson, Arizona • Brooklyn Park, Minnesota • Albuquerque, New Mexico + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Brooklyn Park", "state": "Minnesota" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Sioux Falls", "state": "South Dakota" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00475800" }, { "nct_id": "NCT01470599", "title": "A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "18 Years to 76 Years" }, "enrollment_count": 150, "start_date": "2012-04", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 32, "location_summary": "Oceanside, California • Lafayette, Colorado • Clearwater, Florida + 16 more", "locations": [ { "city": "Oceanside", "state": "California" }, { "city": "Lafayette", "state": "Colorado" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01470599" }, { "nct_id": "NCT05055063", "title": "A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-05-18", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-27T12:52:03.690Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05055063" } ] }